DeepMed Research

ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABT-450
Drug: ritonavir

First Posted Date: 2010-03-24

Last Posted Date: 2010-12-21

Lead Sponsor: Abbott

Target Recruit Count: 40

Registration Number: NCT01091649

Locations: 🇺🇸
Site Reference ID/Investigator# 27781, Waukegan, Illinois, United States

Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis

Completed

Conditions: Parathyroid Hormone

Interventions: Drug: Zemplar iv (paricalcitol iv)

First Posted Date: 2010-03-10

Last Posted Date: 2011-09-21

Lead Sponsor: Abbott

Target Recruit Count: 181

Registration Number: NCT01084538

Locations: 🇭🇷
Site Reference ID/Investigator# 27525, Dubrovnik, Croatia
🇭🇷
Site Reference ID/Investigator# 27531, Imotski, Croatia
🇭🇷
Site Reference ID/Investigator# 6175, Karlovac, Croatia

and more 18 locations

Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs

Completed

Conditions: Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis

First Posted Date: 2010-03-10

Last Posted Date: 2011-08-11

Lead Sponsor: Abbott

Target Recruit Count: 162

Registration Number: NCT01083693

Locations: 🇦🇹
Site Reference ID/Investigator # 32365, Linz, Austria
🇦🇹
Site Reference ID/Investigator # 32368, Bludenz, Austria
🇦🇹
Site Reference ID/Investigator # 32367, Gloggnitz, Austria

and more 17 locations

Evaluation of Kaletra Therapy Over the Long-term

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Lopinavir/Ritonavir (Kaletra)

First Posted Date: 2010-03-10

Last Posted Date: 2011-08-11

Lead Sponsor: Abbott

Target Recruit Count: 284

Registration Number: NCT01083810

Locations: 🇩🇪
Site Ref # / Investigator 52972, Aachen, Germany
🇩🇪
Site Reference ID/Investigator# 27629, Berlin, Germany
🇩🇪
Site Reference ID/Investigator# 27562, Berlin, Germany

and more 87 locations

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

Completed

Conditions: Psoriasis Chronic

First Posted Date: 2010-03-10

Last Posted Date: 2012-06-29

Lead Sponsor: Abbott

Target Recruit Count: 46

Registration Number: NCT01084668

Locations: 🇦🇹
Site Reference ID/Investigator# 27436, Graz, Austria
🇦🇹
Site Reference ID/Investigator# 27440, Vienna, Austria
🇦🇹
Site Reference ID/Investigator# 27435, Feldkirch, Austria

and more 6 locations

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use

Terminated

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-09

Last Posted Date: 2012-01-19

Lead Sponsor: Abbott

Target Recruit Count: 82

Registration Number: NCT01083160

Locations: 🇲🇽
Site Reference ID/Investigator# 27886, Guadalajara, Jal., Mexico
🇲🇽
Site Reference ID/Investigator# 27887, Guadalajara, Jal., Mexico
🇲🇽
Site Reference ID/Investigator# 27885, Mexico City,, Mexico

and more 9 locations

Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

Completed

Conditions: Prostatic Neoplasm

Interventions: Drug: leuprolide (Lucrin/Lucrin-Tri-depot)

First Posted Date: 2010-03-05

Last Posted Date: 2012-10-31

Lead Sponsor: Abbott

Target Recruit Count: 2717

Registration Number: NCT01081873

Locations: 🇧🇪
Site Reference ID/Investigator# 31203, Bruxelles, Belgium
🇧🇪
Site Reference ID/Investigator# 31236, Bruxelles, Belgium
🇧🇪
Site Reference ID/Investigator# 31200, Bruxelles, Belgium

and more 132 locations

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: ABT-072
Drug: Placebo

First Posted Date: 2010-03-05

Last Posted Date: 2010-10-25

Lead Sponsor: Abbott

Target Recruit Count: 24

Registration Number: NCT01081483

Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

Completed

Conditions: Chronic Kidney Failure
Secondary Hyperparathyroidism

First Posted Date: 2010-03-05

Last Posted Date: 2012-03-27

Lead Sponsor: Abbott

Target Recruit Count: 237

Registration Number: NCT01081665

Locations: 🇬🇷
Site Reference ID/Investigator# 32057, Chania, Greece
🇬🇷
Site Reference ID/Investigator# 32055, Athens, Greece
🇬🇷
Site Reference ID/Investigator# 32056, Chalkida, Greece

and more 16 locations

Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus

Completed

Conditions: Hypertension

First Posted Date: 2010-03-03

Last Posted Date: 2011-05-09

Lead Sponsor: Abbott

Target Recruit Count: 15436

Registration Number: NCT01079195

Locations: 🇧🇬
Site Reference ID/Investigator# 29681, Sofia, Bulgaria
🇧🇬
Site Reference ID/Investigator# 29079, Sofia, Bulgaria
🇧🇬
Site Reference ID/Investigator# 29484, Stara Zagora, Bulgaria

and more 895 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy